In the OPERA-TAVI registry, matched patients undergoing TAVI using Evolut PRO/PRO+ and Sapien 3 ULTRA devices exhibited comparable rates of the composite endpoint of all-cause mortality, rehospitalisation for heart failure, or disabling stroke at 1 year. eurointervention.pcronline.com/article/one-ye…

1-year outcomes OPERA-TAVI registry finally out! 👉 No differences in mortality and re-hosp 👉Higher disabling stroke in Evolut PRO/PRO+ (2.6% vs. 0.4%). Selection bias? Real THV effect? It is time for more RCTs! #TAVI EuroIntervention Giuliano Costa eurointervention.pcronline.com/article/one-ye…

#PCRLV coronary access during #TAVR with Alessandro Beneduce Marco Barbanti PCRonline 🫀 simulation learning room is packed 🌟🌟 Edoardo Zancanaro MD Alessandro Sticchi Jonathan Curio Andrea Scotti Victoria Delgado francesco maisano

#PCRLV 2023 🇬🇧 Bringing the “patient” in #SimulationLab learning room for our session on coronary access after #TAVI ❤️ Marco Barbanti Arif Khokhar Martin Swaans #CardioTwitter #CardioEd #MedEd #vhdAS #cvVHD #TAVR

Coronary Access after TAVI Multi-modality teaching using: ⚙️ SIM 🫀 Real valves, 🐷 Real hearts, 📺 Smart screen and Smart people 🤓 Marco Barbanti Alessandro Beneduce @martinandreas Education. Revolution. #PCRLV23

This comprehensive review aims to shed light on dyslipidemia management stratifying effectiveness of novel and advancing lipid-lowering therapy. Available now online on JCM MDPI mdpi.com/2077-0383/13/5… Federica Agnello Marco Barbanti #dyslipidemia #cardiology #jcm #mdpi #lipid

Just out! Coronary overlap w/ commissural alignment in #TAVR is <3% in CT modeling; coronary alignment rarely need. JACC Journals #JACCINT by Mount Sinai Fuster Heart Hospital Dr. Manish Vinayak MD DM FSCAI Parasuram Krishnamoorthy MD et al jacc.org/doi/10.1016/j.……… @Khera_MD David J. Cohen, MD, MSc MIЯVΛƬ #IC Didier Tchetche

In the RE-ACCESS 2 Study unsuccessful coronary cannulation after #Evolut and #Acurate implanted with commissural alignment was 5.5%. Acurate still better than Evolut, but Remarkable improvement compared with RE-ACCESS.Commissural alignment in #TAVI matters JACC Journals

💥TAVR in Small Annuli: SAPIEN ULTRA vs. Evolut PRO JACC Journals 🌐A SMART Trial-like design in a Real-World TAVR Registry 🔗 doi.org/10.1016/j.jcin… Azeem Latib @MatteoMSturla GCosta Marco Barbanti Montefiore Health System Albert Einstein College of Medicine - Official ⏳ What will the SMART RCT show American College of Cardiology?

Self-expanding (SE) Evolut PRO vs balloon-expandable (BE) SAPIEN ULTRA in small annuli: 🔸 SE - superior hemodynamic performance (gradients, PPM) 🔸 BE - less PVL, PPI, stroke 📎 bit.ly/3vntMHB #JACCINT #vhdAS #TAVI

Any crystal ball predictions as to how this will differ from the results of the SMART trial being presented at ACC next month?

This propensity-score matched study may be a foretaste of the SMART trial that will be presented at ACC this week. Evolut PRO and SAPIEN ULTRA Performance in Small Aortic Annuli: The OPERA-TAVI Registry | JACC: Cardiovascular Interventions jacc.org/doi/10.1016/j.…

Is there a simplified left atrial appendage closure pathway? Safety and efficacy of percutaneous closure without preprocedural imaging. A Research Letter Giuliano Costa george ramsay Claudio Sanfilippo Marco Barbanti #cardiotwitter #AHAJournals ahajrnls.org/3XDBKZb

🚨 The #PURPOSE study demonstrated better acute performance of the #JenaValve compared to non-dedicated THVs in those undergoing #TAVR for aortic regurgitation. bit.ly/466COH1 #JACCINT #vhdAR

The Reverse Paradigm: Business Driven Science. The rapid expansion of transcatheter Tx for tricuspid regurgitation, fueled initially by industry’s pursuit of profit following the success of TAVR, has exposed a critical gap in our understanding of the disease—a gap that could

🚨 Final Reminder! Submit by August 25 for #PCRLV to boost your career, expand your network, and get feedback from your peers. Prizes for Best Scientific Abstract, Best Clinical Case, and Best Innovation await. Course Directors dottormaisano, Nicolo Piazza, Bernard Prendergast,

My main takeaway from RHEIA: The first ever RCT only including women sets the scene for TAVI being the default strategy in female<75 with severe AS🔥🔥! Better access, short hospital stay, faster recovery + excellent clinical and echo outcomes.